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The fat-derived hormone leptin binds to its hypotha-
lamic receptors to regulate glucose homeostasis.
Leptin is also synthesized in the stomach and sub-
sequently binds to its receptors expressed in the
intestine, although the functional relevance of such
activation remains largely unknown. We report here
that intrajejunal leptin administration activates jeju-
nal leptin receptors and signals through a phos-
phatidylinositol 3-kinase (PI3K)-dependent and
signal transducer and activator of transcription 3
(STAT3)-independent signaling pathway to lower
glucose production in healthy rodents. Jejunal leptin
action is sufficient to lower glucose production
in uncontrolled diabetic and high-fat-fed rodents
and contributes to the early antidiabetic effect of
duodenal-jejunal bypass surgery. These data unveil
a glucoregulatory site of leptin action and suggest
that enhancing leptin-PI3K signaling in the jejunum
lowers plasma glucose concentrations in diabetes.
INTRODUCTION
The discovery of leptin (Zhang et al., 1994) led to the findings that
indicate that leptin binds to the hypothalamic long-form leptin re-
ceptor (Leprb) to regulate energy balance (Morton et al., 2006;
Myers and Olson, 2012). While central leptin activates hypotha-
lamic phosphatidylinositol 3-kinase (PI3K) and signal transducer
and activator of transcription 3 (STAT3) to improve insulin sensi-
tivity (Morton et al., 2005) and lower glucose production (GP)
(Buettner et al., 2006) in high-fat-fed rodents, leptin also lowers
GP and glucose levels in streptozotocin (STZ)-induced diabetic
rodents (German et al., 2011; Fujikawa et al., 2010).
Leptin action, however, is not limited to the hypothalamus, as
hindbrain leptin signaling lowers food intake (Hayes et al., 2010).
In addition, leptin is synthesized in the stomach and secreted to
the intestinal lumen in response to nutrients (Bado et al., 1998;
Cammisotto and Bendayan, 2012). Leptin receptors, STAT3,Celland PI3K are expressed in the intestine and/or on the intestinal
vagal terminals (Buyse et al., 2001; Morton et al., 1998; Sheng
et al., 2003; Heldsinger et al., 2011), and intestinal leptin
signaling maintains mucosal integrity (Guo et al., 2011; Duggal
et al., 2011). Whether intestinal leptin signaling regulates glucose
metabolism has not been tested.
Given that leptin triggers the CNS to control glucose (Schwartz
and Porte, 2005; Howard et al., 2004) while intestinal vagal
innervation mediates nutrient sensing to regulate glucose via a
gut-brain axis (Rasmussen et al., 2012; Breen et al., 2012), we
postulate that intestinal leptin activates a leptin receptor-PI3K
and/or STAT3 pathway to regulate glucose homeostasis through
a neuronal network. Jejunal nutrient sensing is necessary for
duodenal-jejunal bypass (DJB) surgery to lower GP (Breen
et al., 2012), and brain leptin action has similar effects (German
et al., 2011; Fujikawa et al., 2010), in diabetes. We assess
whether intestinal leptin action is intact in diabetic or high-fat-
fed rodents and necessary for the antidiabetic effect of DJB.RESULTS AND DISCUSSION
Jejunal Leptin Activates Leptin Receptors to Lower GP
Consistent with previous reports (Buyse et al., 2001; Iqbal et al.,
2010; Barrenetxe et al., 2002; Morton et al., 1998; Cammisotto
and Bendayan, 2012), PCR and western blot analyses revealed
Leprb expression in the duodenum and jejunum of rats (Fig-
ure S1A available online). Using the same anti-Leprb as the cur-
rent study, studies documented an120–130 kDa band as Leprb
in the vagus nerves and hypothalamus of rats (Buyse et al., 2001;
Shioda et al., 1998). Specificity of the anti-Leprb is confirmed
with a blocking peptide (Figure S1A). Rats underwent a pancre-
atic-euglycemic clamp (Table S1; basal is averaged from 60–90,
min and clamp is averaged from 180–200 min) where leptin was
infused into the duodenum or jejunumduring the final 50min (i.e.,
150–200 min) (Figure 1A). Intraduodenal leptin infusion did not
alter the glucose infusion rate (Figure 1B), GP (Figures 1C and
S1B), or glucose uptake (Figure S1C). Intrajejunal leptin infusion
instead increased glucose infusion rate (Figure 1B) and lowered
GP (Figures 1C and S1B) compared to saline. Glucose uptake
(Figure S1C), plasma insulin, and glucose levels (Table S1) did
not change. Intrajejunal leptin infusion did not increase plasmaMetabolism 19, 155–161, January 7, 2014 ª2014 Elsevier Inc. 155
Figure 1. Jejunal Leptin Activates Leptin Receptors to Lower GP in Rats and Mice
(A) Schematic representation of the working hypothesis: gastric leptin activates an intestinal Leprb receptor-PI3K- and/or STAT3-dependent pathway to regulate
GP via a neuronal network.
(B and C) We measured the glucose infusion rate (B) and glucose production (C) during the clamp (**p < 0.01 jejunal leptin versus other groups).
(D) Plasma leptin levels before (basal) and at the end of the clamp. Portal leptin levels at the end of the clamp.
(E) Glucose production during the clamp in lean (Fa/Fa) or leptin receptor-deficient obese (fak/fak) Koletsky rats (**p < 0.01 versus other groups).
(F) Glucose production during the clamp in C57BL/6 or leptin receptor-deficient db/db mice (**p < 0.01 versus other groups). Values are shown as mean + SEM.
n = 5–7 rats per group; n = 7–8 mice per group. SLR, soluble leptin receptor. See also Figure S1 and Table S1.
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(Figure 1D) or portal leptin levels at the end (Figure 1D). To ensure
that GP lowering occurred independently of changes in plasma
leptin, we infused intravenous leptin at a dose and duration equal
to that of intrajejunal leptin and found that glucose metabolism
was unaltered (Figures S1D–S1F). Thus, an intrajejunal leptin
infusion lowers GP independently of changes in plasma leptin,
insulin, and glucose levels.
To assess the role of jejunal leptin receptors, we first infused
leptin with a soluble leptin receptor (SLR) that antagonizes lep-
tin’s effects (Zhang and Scarpace, 2009). Infusion of intrajejunal
SLR for 50 min did not alter glucose metabolism (Figures 1B, 1C,
S1B, and S1C) but negated the effect of leptin (Figures 1B, 1C,
S1B, and S1C). Second, intrajejunal leptin infusion increased
glucose infusion rate (Figure S1G) and lowered GP (Figures 1E
and S1H) with no changes in glucose uptake (Figure S1I)
compared to saline in lean Fa/Fa rats. To match the body weight
to the Fa/Fa rats, we limited food intake of leptin receptor-defi-
cient obese (fak/fak) Koletsky fak/fak rats (Morton et al., 2005).
Intrajejunal leptin infusion failed to alter glucose metabolism
compared to saline in the weight- and age-matched fak/fak rats
(Figures 1E and S1G–S1I).
We subjected conscious mice to a pancreatic (basal insulin)
clamp while intrajejunal leptin was infused for 50 min. Intrajejunal
leptin infusion increased glucose infusion rate (Figure S1J) and
lowered GP (Figures 1F and S1K), with no changes in glucose
uptake (Figure S1L) compared to saline in C57BL/6J mice. This156 Cell Metabolism 19, 155–161, January 7, 2014 ª2014 Elsevier Inoccurred independent of plasma leptin since intravenous leptin
infused at a dose and duration equal to that of intrajejunal leptin
did not alter glucosemetabolism (Figures S1M–S1O). Intrajejunal
leptin infusion failed to alter the glucose infusion rate (Figure S1J)
and GP (Figures 1F and S1K) in the weight- and age-matched
leptin receptor-deficient obese db/db mice. Thus, jejunal leptin
receptor is required for intrajejunal leptin infusion to lower GP
in rats and mice.
Jejunal Leptin Activates a STAT3-Independent and
PI3K-Dependent Pathway to Lower GP via a Neuronal
Network
We infused the STAT3 peptide inhibitor (STAT3 PI) with leptin
into the jejunum for 50 min and found that STAT3 PI failed to
reverse the GP-lowering effect of leptin (Figures 2A, 2B, S2A,
and S2B) but negated the ability of leptin to increase jejunal
STAT3 phosphorylation (Y705) (Figure 2C).
We next infused PI3K inhibitor LY294002 or wortmannin
with leptin into the jejunum for 50 min. Intrajejunal infusion of
LY294002 or wortmannin alone did not affect glucose meta-
bolism (Figures 2A, 2B, S2A, and S2B) but abolished the effect
of leptin to lower GP (Figures 2A, 2B, S2A, and S2B) and activate
jejunal PI3K activity (Figure 2D). Intrajejunal leptin failed to acti-
vate PI3K in the presence of SLR infusion (Figure 2D). Intrajejunal
leptin infusion did not activate duodenal PI3K (Figure S2C)
or hypothalamic STAT3 (Figure S2D). Further, intraduodenal
leptin infusion activated duodenal STAT3 (Figure S2E), but notc.
Figure 2. Jejunal Leptin Activates a STAT3-Independent and PI3K-Dependent Pathway to Lower GP via a Neuronal Network
(A and B) We measured the glucose infusion rate (A) and glucose production (B) during the clamp (**p < 0.01 leptin or leptin + STAT3 PI versus other groups).
(C) The level of phosphorylation of STAT3 analyzed by western blot and expressed as fold increase over saline in the jejunum obtained at the end of the clamp
(*p < 0.05 versus other groups). A representative immunoblot is shown.
(D) PI3K activity in the jejunum at the end of the clamp expressed as fold increase over saline (*p < 0.05 versus other groups).
(E andF)Wemeasured the glucose infusion rate (E) andglucoseproduction (F) during the clamp (**p<0.01 versus other groups). Values are shownasmean+SEM.
n = 5–7 rats per group. STAT3 PI, signal transducer and activator of transcription 3 peptide inhibitor; PI3K, phosphatidylinositol 3-kinase. See also Figure S2.
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that the inability of duodenal leptin to lower GP (Figure 1C) is due,
secondarily, to an absence of PI3K activation, studies are
needed to address this possibility as well as the reasons behind
the inability of duodenal leptin to activate PI3K.
We infused tetracaine into the jejunum for 50 min to inhibit
neurotransmission of the nerves that innervate the jejunum while
leptin was infused. Intrajejunal tetracaine alone did not affect
glucose metabolism but negated the effect of leptin (Figures
2E, 2F, S2G, and S2H). Thus, jejunal PI3K and neuronal transmis-
sion are necessary for leptin to lower GP.
Jejunal Leptin Lowers GP in High-Fat-Fed or Diabetic
Rats
The antidiabetic effect of leptin (Wang et al., 2010; Chinookos-
wong et al., 1999) is attributed to the brain (Fujikawa et al.,
2010; German et al., 2011). In parallel, hypothalamic leptin
lowers GP in 3 day high-fat-fed rats (Buettner et al., 2006). We
tested jejunal leptin action in the same 3 day high-fat-fed model
that we characterized as having duodenal cholecystokinin resis-
tance as well as insulin resistance (Cheung et al., 2009; Rasmus-
sen et al., 2012; Chari et al., 2008). Intrajejunal leptin infusion for
50 min increased glucose infusion rate (Figure S3A) and lowered
GP (Figures 3A and 3B) compared to saline, with no changes in
glucose uptake (Figure S3B) in high-fat-fed rats. Intravenous
leptin infused at a dose and duration equal to that of intrajejunal
leptin did not alter glucose metabolism (Figures S3C–S3E), indi-
cating that jejunal leptin-GP inhibitory action is specific to the
jejunum in high-fat-fed rats.CellWe injected rats with STZ to elevate plasma glucose levels and
GP to 340 mg/dl (Figure 3C) and 23 mg/kg/min (Figure 3D),
respectively, and reduce insulin levels by 80% (Figure 3E). In
nonclamped conditions, infusion of intrajejunal leptin for 50 min
reduced plasma glucose levels (Figure 3C) and GP (Figure 3D)
compared to saline in this STZ-uncontrolled diabetic model
independent of changes in plasma insulin (Figure 3E) and
glucagon (Figure 3F) levels. Intravenous leptin infused at the
same dose and duration had no effect (Figures S3F and S3G),
indicating that the jejunal leptin-GP inhibitory action is specific
to the jejunum in diabetes.
Jejunal Leptin Action Mediates the Antidiabetic Effect
of DJB
We inhibited jejunal leptin action in uncontrolled diabetic rats that
received DJB while we monitored plasma glucose levels during
refeeding. This experimental design is based on the fact that re-
feeding will stimulate leptin secretion from the gastric chief cells
into the lumen (Bado et al., 1998; Guilmeau et al., 2003), form a
complex with its jejunal receptors (Cammisotto and Bendayan,
2012), and possibly lower plasma glucose levels in DJB-diabetic
rats. DJB or sham surgery was performed (Rubino and Mares-
caux, 2004) in STZ-diabetic rats (Figure 4A). DJB reduced fed
plasma glucose levels compared to sham in STZ-diabetic rats
within 2 days after surgery (Figure 4B). This effect was not asso-
ciated with changes in plasma insulin (Figure 4C) or glucagon
(Figure 4D) levels or changes in food intake (before surgery,
STZ-SHAM 27 g ± 0.7 g and STZ-DJB 31 g ± 1.3 g; 2 days after
surgery, STZ-SHAM4 g ± 1.3 g and STZ-DJB 5 g ± 1.4 g) or bodyMetabolism 19, 155–161, January 7, 2014 ª2014 Elsevier Inc. 157
Figure 3. Jejunal Leptin Lowers GP in High-Fat-Fed or Uncontrolled Diabetic Rats
(A and B) We measured the glucose production (A) and the percent suppression of glucose production (B) during the clamp (**p < 0.01 leptin versus saline).
(C–F) We measured the plasma glucose levels (C), glucose production (D), plasma insulin (E), and glucagon levels (F) in nonclamped conditions in STZ-diabetic
rats (*p < 0.05 leptin versus saline). Values are shown as mean + SEM. n = 5–6 rats per group. STZ, streptozotocin. See also Figure S3.
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Gut Leptin and Glucose Controlweight (before surgery, STZ-SHAM 301 g ± 11.2 g and STZ-DJB
314 g ± 4.3 g; 2 days after surgery, STZ-SHAM 291 g ± 14.5 g
and STZ-DJB 305 g ± 8.8 g).
We then inserted a jejunal catheter in conjunction with DJB in
STZ-diabetic rats (Figure 4A). We carried out a fasting-refeeding
experiment to promote gastric leptin secretion while infusing the
SLR directly into the jejunum to disrupt jejunal leptin signaling
(Figure 4A) in STZ-diabetic rats 2 days after DJB. We monitored
plasma glucose levels for 50 min during refeeding in an attempt
to match the duration of intrajejunal leptin infusion (Figures 1B
and 1C). Glucose control during refeeding was intact in STZ-
DJB diabetic rats that received intrajejunal saline infusion as
compared to STZ-SHAM (Figure 4E, top panel) and independent
of changes in food intake (Figure 4F). In contrast, intrajejunal
infusion of SLR into the STZ-DJB rats disrupted the glucose
control observed in the STZ-DJB intrajejunal saline-infused
rats during refeeding (Figure 4E, bottom panel). The glucose
control disruption occurred independently of changes in food
intake (Figure 4F) but did not reach that of STZ-SHAM jejunal
saline-infused rats (Figure 4E, top panel). Nonetheless, gastric
leptin action in the jejunum contributes to the rapid (2 day)
glucose-lowering effect induced by DJB in diabetes.
Our discovery revises the traditional view of leptin action and
suggests that, alternatively to the brain (Morton and Schwartz,
2011), leptin activates jejunal PI3K to lower GP. The physiolog-
ical relevance of intestinal leptin action remains to be clarified,
as jejunal, but not duodenal, leptin lowers GP, and short-term in-
hibition of jejunal leptin receptor-mediated action (via intrajejunal
SLR or PI3K inhibitors infusion) per se did not alter GP.
With molecular and chemical approaches, we demonstrated
that jejunal leptin receptor is required for intrajejunal leptin infu-158 Cell Metabolism 19, 155–161, January 7, 2014 ª2014 Elsevier Insion to activate jejunal PI3K and lower GP. It remains to be as-
sessed whether STAT5 and SOCS3 are targets of jejunal leptin,
since both are expressed in the intestine (Morton et al., 1998; de
Lartigue et al., 2011) and are the targets of hypothalamic leptin
action (Banks et al., 2000; Gong et al., 2007). For reasons yet un-
known, jejunal leptin-PI3K signaling, but not STAT3 signaling,
lowers GP. Although the role of intestinal STAT3 warrants future
investigation, a potential effector of jejunal PI3K is the voltage-
gated sodium channels, as tetracaine (an inhibitor of voltage-
gated sodium channels) abolished the effect of leptin. In fact,
one study indicates that PI3K alters sodium conductance
(Tong et al., 2004), while no such parallel studies exist for
STAT3, to our knowledge. The site(s) of leptin-PI3K signaling in
the gastrointestinal (GI) tract remains unclear, as current data
only narrowed the action to the jejunum (i.e., jejunal mucosa
and/or the vagal nerves that innervate the jejunum) at best.
Nonetheless, it is clear that jejunal neuronal innervation is
required for the GP-lowering effect of leptin.
Cholecystokinin (CCK) activates CCK-1 receptor-PKA
signaling in the duodenum and a neuronal axis to inhibit GP
(Cheung et al., 2009; Rasmussen et al., 2012), while inhibition
of intestinal dipeptidyl peptidase-4 leads to activation of vagal
afferent firing and improves glucose tolerance in diet-induced
obese rodents (Waget et al., 2011). Together with the current dis-
covery on leptin, these studies indicate that hormones bind to
their receptors expressed in the GI tract and trigger the CNS to
regulate glucose homeostasis. Leptin enhances intestinal CCK
to decrease feeding in the brain (Morton et al., 2006; Hayes
et al., 2010) and possibly in the intestine (de Lartigue et al.,
2010; Heldsinger et al., 2011) where both the CCK-1 receptor
(Patterson et al., 2002) and the Leprb (Buyse et al., 2001) arec.
Figure 4. Jejunal Leptin Action Mediates the Rapid Antidiabetic Effect of DJB
(A) Schematic representation of the sham and DJB surgical procedure and jejunal catheter placement.
(B) Fed plasma glucose levels obtained in STZ-induced diabetic rats 2 days after sham or DJB surgery (*p < 0.05).
(C and D) Fed plasma insulin (C) and glucagon (D) levels obtained in rats before STZ injection, after STZ injection (before surgery), and 2 days after surgery
(in C, **p < 0.01 versus other groups).
(E) Top: plasma glucose levels during refeeding in STZ-diabetic rats with DJB versus SHAM surgery and infused with intrajejunal saline. Bottom: plasma glucose
levels during refeeding in STZ-diabetic rats with DJB surgery and infused with intrajejunal saline or the SLR (f = STZ-DJB-jejunal saline versus STZ-SHAM-jejunal
saline; * = STZ-DJB-jejunal saline versus STZ-DJB-jejunal SLR; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 [same for both symbols]).
(F) Accumulated food intake during the refeeding protocol. Values are shown as mean + SEM. n = 5–6 rats per group.
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to regulate GP.
Jejunal leptin signaling may be therapeutically relevant, as an
intrajejunal leptin infusion lowers GP in high-fat-fed rats. High-fat
feeding for 3 days induces leptin resistance (Wang et al., 2001)
but did not disrupt the ability of direct leptin infusion into the brain
(Buettner et al., 2006) or jejunum to lower GP. The potential role
of jejunal leptin action and the neuronal network in lowering
glucose in chronic obese models remains to be clarified. In
STZ-uncontrolled diabetic rodents, peripheral and central infu-
sion of leptin normalizes plasma glucose levels in parallel to
lowering hyperglucagonemia (Wang et al., 2010; German et al.,
2011; Fujikawa et al., 2010). We demonstrated that jejunal leptin
action lowers (but does not normalize) plasma glucose levels
through an inhibition of GP in STZ-diabetic rodents indepen-
dently of changes in circulating glucagon levels. Plasma
glucagon levels, however, were not elevated to begin with in
this early-onset diabetic model. In the same diabetic model, jeju-
nal nutrient sensing lowers GP independently of a lowering of
plasma glucagon levels as well (Breen et al., 2012). A contribu-
tion of glucagon action in mediating leptin’s effect may become
apparent in chronic uncontrolled diabetes.
During refeeding, nutrient influx stimulates the release of hor-
mones (Liddle et al., 1985; Herrmann et al., 1995; Adrian et al.,Cell1985) such as gastric leptin (Bado et al., 1998). The role of gut
peptides inmediating theglucose-lowering effect ofDJB remains
debatable (Jiao et al., 2013; Troy et al., 2008; Breen et al., 2012),
and the involvement of bile acids is becoming apparent (Pourna-
ras et al., 2012). In light of the redirected route of delivery from the
stomach into the jejunum achieved by DJB, gastric leptin release
and the subsequent activation of the jejunal leptin receptors may
partly mediate the rapid antidiabetic effects of DJB. Examining
whether jejunal leptin and nutrient sensing converge may shed
light on mechanisms that are required. The role of jejunal leptin
action in the antidiabetic effect of other forms of bariatric surgery
in obese and diabetic models also remains to be clarified.
In summary, we unveil the jejunum as a site of leptin action that
triggers a jejunal leptin receptor-PI3K-dependent pathway to
lower GP. Direct activation of jejunal leptin signaling lowers GP
in high-fat-fed or uncontrolled diabetic rodents and is necessary
for the rapid antidiabetic effect of DJB surgery. Targeting jejunal
leptin signaling may serve as a therapeutic strategy by which to
lower glucose levels in diabetes.EXPERIMENTAL PROCEDURES
The Institutional Animal Care and Use Committee of the University Health
Network approved all procedures in rats and mice. Please see theMetabolism 19, 155–161, January 7, 2014 ª2014 Elsevier Inc. 159
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dures performed.
Animal Preparation
We obtained 8-week-old male Sprague-Dawley rats (280–300 g) and 8-week-
old male lean and obese leptin receptor-deficient Koletsky rats from Charles
River Laboratories and 6- to 7-week-old obese leptin receptor-deficient
male db/db mice and 18-week-old C57BL/6J mice from Jackson Laboratory.
A separate group of male Sprague-Dawley rats was placed on a lard-oil-
enriched high-fat diet for 3 days as described (Rasmussen et al., 2012), while
another set of rats was induced with uncontrolled diabetes via a single intra-
peritoneal (i.p.) injection of streptozotocin (STZ; 65 mg/kg; a potent diabeto-
genic agent that is cytolytic against pancreatic b cells). We dissolved STZ in
saline and administered it 5–6 days before sham or DJB surgery or 4 days
before jejunal and vascular surgeries. We included only rats that were hyper-
glycemic (plasma glucose levels > 300 mg/dl) in the study.
Intestinal and Vascular Cannulations in Rodents
Jejunal, duodenal, intravenous, and arterial cannulations were performed as
described (Breen et al., 2012).
Rat and Mouse Pancreatic-Euglycemic Clamp Procedure
The infusion clamp was performed as described (Breen et al., 2012; Rasmus-
sen et al., 2012; Filippi et al., 2012) in rats with caloric intake restricted to
56 kcal the night before (lasting a total of 200 min) and in mice with caloric
intake restricted to 12 kcal the night before (lasting a total of 170 min). Intraje-
junal or intraduodenal continuous infusion (0.01 ml/min for rats and 2 ml/min for
mice) was performed from t = 150 to t = 200 in rats and from t = 120 to t = 170
in mice.
Treatments
The following substances were infused through a jejunal or duodenal catheter
in rats: (1) saline, (2) leptin (6.7 ng/min), (3) soluble leptin receptor (SLR)
(1 mg/min), (4) STAT3 PI (15 pmol/min), (5) wortmannin (0.002 nmol/min), (6)
LY294002 (0.2 nmol/min), and (7) tetracaine (0.01 mg/min). Solutions 2–4
were dissolved in saline, while solutions 5–7 were dissolved in 5% DMSO. In
mice, saline or leptin (6.7 ng/min) was infused intrajejunally.
Gut Tissue Collection and Preparation for Western Blotting and
Enzymatic Activity Assay,WesternBlotting, RNAExtraction andPCR
Methods, and PI3K Activity Assay
Please see Supplemental Experimental Procedures for detailed descriptions.
Duodenal-Jejunal Bypass Surgery
The surgical procedure was performed as described (Breen et al., 2012)
(Figure 4A).
Fasting-Refeeding Protocol
Rats were fasted at 5 pm the day before the experiment. Saline or SLR
(1 mg/min) was preinfused into the jejunum for 10 min, and then regular
chow was given back to the animals ad libitum. The jejunal infusion was main-
tained for 50 min to match the treatment during the clamp studies.
Biochemical Analysis
We measured plasma glucose concentrations using the glucose oxidase
method (GM9 Glucose Analyzer, Analox Instruments). For plasma hormone
measurements, plasma was collected into heparinized tubes on ice, sepa-
rated, and stored at 20C. Plasma leptin, insulin, and glucagon levels were
determined by radioimmunoassay (RIA) (Linco Research).
Calculations
Unpaired Student’s t test was performed in statistical analyses of two groups.
Where comparisons were made across more than two groups, ANOVA
was performed; if significant, this was followed by Tukey’s post hoc test,
which enabled comparisons of all treatment groups. Data are presented as
means ± SEM. The time period of 60–90 min was averaged for the basal con-
dition, and the time period of 180–200 min was averaged for the clamp
condition.160 Cell Metabolism 19, 155–161, January 7, 2014 ª2014 Elsevier InSUPPLEMENTAL INFORMATION
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